Meeting
2018 Genitourinary Cancers Symposium
Cardiovascular comorbidities in German prostate cancer patients under androgen deprivation therapy: Results from a retrospective analysis of patient data in urological outpatient centers.
Authors
Andreas Eisenhardt
PURR, Mülheim an der Ruhr, Germany
Andreas Eisenhardt , Sebastian Vosgerau , Michael Gedamke , Tim Schneider
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 339)
DOI
10.1200/JCO.2018.36.6_suppl.339
Abstract #
339
Poster Bd #
D8
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Duration of the anti-androgen in men undergoing six months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death.
First Author: Nina Niu Sanford
Poster
2016 Genitourinary Cancers Symposium
Incidence of testosterone escape with LHRH agonists in patients receiving radiotherapy for prostate cancer.
First Author: Derek R Wilke
Poster
2014 Genitourinary Cancers Symposium
Degarelix monotherapy versus luteinizing hormone-releasing hormone (LHRH) agonists plus antiandrogen flare protection in the treatment of men with advanced prostate cancer.
First Author: Bertrand Tombal
Poster
2023 ASCO Annual Meeting
Propensity score matched analysis of major adverse cardiac events in patients with localized prostate cancer receiving short term vs long term ADT.
First Author: Ye Yuan